CAPR (Capricor Therapeutics) Short Ratio


CAPR Capricor Therapeutics Inc CAPR
37 GF Score
Price $23.21
GF Value $4.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CAPR
37GF Score
Capricor Therapeutics Inc CAPR
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Capricor Therapeutics (CAPR) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued. The current stock price of $23.21 is trading 376.6% above its estimated GF Value™ of $4.87. GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.

Key valuation signals for CAPR:

  • Short Ratio:
  • GF Value™: $4.87 vs. price of $23.21 (376.6% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score

Get the complete analysis for CAPR

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.21
Price
$4.87
GF Value